RxDoctor Payments Data

Kregg Bly

Optometrist · Jackson, MSNPI 1679672729

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 80 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by Alcon at 27.2% of the total.

$2,761in general payments, 2019–2025

Across 80 payments — averaging $34.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$750
  • Coopervision Inc.$384
  • Bausch & Lomb Americas Inc.$334
  • AbbVie$289
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$220
  • Aerie Pharmaceuticals, Inc.$207
  • plus $577 from 6 others

What the payments were for

  • Food & beverage$2,761100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,761 in reported general payments places this provider in the 80th percentile of 372 optometrist providers in Mississippi.

See all optometrist providers in Mississippi

Medicare billing

Part B allowed, 2024
$14,833
Medicare patients
76
Services billed
238

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost225$116,102
VyzultaLatanoprostene Bunod143$54,636
RestasisCyclosporine15$14,870
CombiganBrimonidine Tartrate/Timolol43$13,688
Azelastine Hcl192$7,708
Latanoprost688$6,814
RocklatanNetarsudil Mesylat/Latanoprost14$4,693
Alphagan PBrimonidine Tartrate21$4,511
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol30$3,519
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat123$2,345
Brimonidine Tartrate76$1,753
Tobramycin-DexamethasoneTobramycin/Dexamethasone27$1,415
Timolol Maleate88$1,180

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan, Alphagan P$289$149,171304 claims
Bausch & Lomb Americas Inc.Vyzulta$334$54,636143 claims
Aerie Pharmaceuticals, Inc.Rocklatan$207$4,69314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 372 optometrist providers in Mississippi.

Other optometrist in Jackson

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →